2018 AVBCC Summit


October 30-31, 2018 | New York Athletic Club, New York, NY

The Association for Value-Based Cancer Care (AVBCC) invites you to attend the 2018 AVBCC Summit in New York, NY on October 30-31, 2018. This is a prime opportunity to gain a thorough understanding of the evolution of the value equation as it relates to cancer therapies and discover how to implement, improve, and sustain your company or institution, while improving access for patients and ultimately patient care.

Top 3 Reasons to Attend the 2018 AVBCC Conference

  • Stay competitive in the ever-changing field of oncology participating in sessions on topics including Health Policy, Telemedicine, Practice Management, Oncology Specialty Pharmacy and Supply Chain, and more.
  • Learn from stakeholders within the cancer care spectrum, including practitioners, pharmacists, payers, and policymakers to improve patient care and maximize patient access and outcomes through care coordination.
  • Network with nationally recognized experts, faculty speakers, panelists, key opinion leaders, C-suite executives, and managers to exchange best practices in advanced value-based performance and quality measures in cancer care.

No other meeting brings together so many key perspectives in cancer care.

Invited Faculty

    • Maggie Adamski
    • Senior Director
    • Patient Insights and Engagement, ICON
    • Sheila Arquette, RPh
    • Executive Director
    • National Association of Specialty Pharmacy
    • Peter Bach, MD
    • Director, Center for Health Policy & Outcomes
    • Memorial Sloan Kettering Cancer Center
    • Kim Blackwell, MD
    • VP, Early Phase Development & Immuno-Oncology
    • Eli Lilly and Company
    • Jeffrey Bockman, PhD
    • Executive Vice President, Oncology Practice Head
    • Defined Health, a Cello Health business
    • Rohit Borker, PhD
    • Vice President and Head, Health Economics and Outcomes Research
    • Novartis Oncology
    • Joel Brill, MD
    • Chief Medical Officer
    • Predictive Health, LLC
    • Barry Brooks, MD
    • Chairman, Contracting Subcommittee
    • US Oncology Network
    • Randy Burkholder
    • VP, Policy & Research
    • PhRMA
    • Rob Butcher
    • Executive Director
    • Swim Across America
    • Virginia Calega, MD, MBA, FACP
    • VP, Medical Management & Policy
    • Independence Blue Cross
    • Nicole Caswell
    • Executive Director of Operations
    • CoPilot Provider Services
    • Anthony Coletta, MD, MBA
    • President, Facilitated Health Networks
    • Independence Blue Cross
    • Charlie Coltman
    • Founder
    • CancerLife
    • Brian DeBusk, PhD, MBA
    • CEO & President, DeRoyal Industries
    • Vice Chairman/Commissioner, MedPAC
    • Michael DeLeo, MD
    • Chief, Radiology
    • Southern New Hampshire Medical Center
    • Luis Diaz, MD
    • Head, Division of Solid Tumor Oncology
    • Memorial Sloan Kettering Cancer Center
    • Mikael Dolstein, MD, PhD
    • President, Worldwide Research & Development
    • Pfizer, Inc
    • Christian Downs, JD, MHA
    • Executive Director
    • Association of Community Cancer Centers
    • Eric Dozier, BS, MBA
    • VP, North American Oncology
    • Eli Lilly and Company
    • Matt Farber, MS
    • Senior Director, Patient Care and Advocacy, Oncology & Fertility
    • Walgreens
    • Brenton Fargnoli, MD
    • Director
    • Flatiron Health
    • A. Mark Fendrick, MD
    • Director
    • University of Michigan Center for Value-Based Insurance Design
    • Christine Ferro, CHFP
    • Healthcare Analytics Consultant
    • Milliman
    • C. Lyn Fitzgerald
    • SVP, US & Global Development
    • National Comprehensive Cancer Network
    • Michael Fitzgibbons
    • Chief Executive Officer
    • Claritas Rx
    • William Flood, MD, MSc
    • Chief Medical Officer
    • eviti NantHealth
    • Liz Fowler, PhD
    • VP, Global Health Policy
    • Johnson & Johnson
    • Bedrick Gadea, PhD
    • Managing Partner
    • The Dedham Group
    • Lisa Gill, CPA
    • Senior Analyst
    • Healthcare Technology and Distribution
    • JPMorgan Securities, Inc
    • Scott Gottlieb, MD
    • Commissioner
    • US Food and Drug Administration
    • Bruce Gould, MD
    • Medical Director
    • Northwest Georgia Oncology Centers, P.C
    • J. Lance Grady
    • Vice President/Team Lead
    • Market Access & Reimbursement
    • Avalere Health
    • Lindsay Greenleaf
    • Director
    • ADVI Health LLC
    • Jennifer Hinkel, MPH
    • Partner
    • McGivney Global Advisors
    • Brad Hirsch, MD
    • Chief Executive Officer
    • SignalPath Research
    • Axel Hoos, MD, PhD
    • SVP, Therapeutic Area Head, Oncology R&D
    • GlaxoSmithKline
    • Kevin Host, PharmD
    • President & COO
    • Pharmaceutical Strategies Group
    • Clifford Hudis, MD, FACP, FASCO
    • Chief Executive Officer
    • American Society of Clinical Oncology
    • Anna Kaltenboeck
    • Program Director and Senior Health Economist, Center for Health Policy & Outcomes
    • Department of Epidemiology & Biostatistics
    • Memorial Sloan Kettering Cancer Center
    • Daniel Klein
    • President/CEO
    • Patient Access Network Foundation
    • Michael Kolodziej, MD
    • VP/Chief Innovation Officer
    • ADVI Health LLC
    • Brian Korb
    • Managing Director
    • Solebury Trout
    • Crystal Kuntz
    • VP, Healthcare Policy & Research
    • Biotechnology Innovation Organization (BIO)
    • Ellen Lukens
    • Division Director, Ambulatory Payment Models
    • Center for Medicare & Medicaid Innovation
    • Centers for Medicare & Medicaid Services
    • Steve Lundquist
    • 4-Time Olympic Gold Medalist & World Record Holder
    • Sumner Madden
    • Senior Director, Access Services
    • AstraZeneca
    • Ash Malik, MBA
    • President, Life Sciences Division
    • Integra Connect, LLC
    • DeWayne Manning, RPh
    • Partner
    • Archbow Consulting
    • Maurie Markman, MD
    • President
    • CTCA Medicine & Science
    • Rusty Massey
    • VP, Provider Relations
    • AmerisourceBergen Specialty Group
    • US Bioservices
    • William McGivney, PhD
    • Managing Principal
    • McGivney Global Advisors
    • John McManus
    • President & Founder
    • The McManus Group
    • Geoff Meacham, PhD
    • Managing Director, Biotech & Pharma Research
    • Barclays
    • Robert S. Miller, MD
    • Vice President and Medical Director of CancerLinQ
    • American Society of Clinical Oncology
    • Marcus Neubauer, MD
    • VP and Medical Director, Value-Based Reimbursement
    • McKesson Specialty Health
    • Brenda Nevidjon, RN, MSN, FAAN
    • Chief Executive Officer
    • Oncology Nursing Society
    • Everett Neville, RPh
    • EVP, Strategy, Supply Chain & Specialty
    • Express Scripts
    • Ben Newton, PhD
    • Global Head
    • GE Healthcare Life Sciences Molecular Imaging
    • Amy Niles, MBA
    • VP, External Relations
    • PAN Foundation
    • Kimberly Noonan, PhD
    • Founder & CSO
    • WindMIL Therapeutics
    • Andrew Norden, MD, MPH, MBA
    • Chief Medical Officer
    • Cota Healthcare
    • Kavita Patel, MD, MS, FACP
    • Nonresident Fellow
    • Brookings Institution
    • Steve Peskin, MD, MBA, FACP
    • Executive Medical Director, Population Health
    • Horizon BCBS
    • Chad Pettit
    • Biosimilars Value and Access
    • Amgen
    • Scooter Plowman, MD, MBA, MHSA
    • Head, Clinical Solutions
    • Proteus Digital Health, Inc
    • Scott Reid, PharmD
    • President
    • eviCore Health
    • Robert Rifkin, MD, FACP
    • Medical Director, Biosimilars
    • US Oncology Network
    • Morrie Ruffin
    • Managing Director
    • Adjuvant Global Advisors, LLC
    • Peter Saltonstall
    • President & CEO
    • National Organization for Rare Disorders
    • Marc Samuels, JD, MPH
    • Founder & CEO
    • ADVI Health LLC
    • Chuck Saunders
    • Chief Executive Officer
    • Integra Connect
    • Dennis Scanlon, PhD
    • Distinguished Professor of Health Policy & Administration
    • Director, Center for Health Care and Policy Research
    • The Pennsylvania State University
    • Theresa Schmidt, MA, PMP, CSPO
    • Director
    • Discern Health
    • Jeffrey Scott, MD
    • Chief Medical Officer
    • Integra Connect, LLC
    • Brian Seiz, PharmD
    • President
    • Accredo Specialty Pharmacy
    • John Simmons, PhD
    • Director, Translational Science & Diagnostics
    • PGDx
    • Greg Simon, JD
    • President
    • Biden Cancer Initiative
    • Surya Singh, MD
    • Corporate VP, Medical Benefit Management
    • CVS Caremark
    • Stan Skrzypczak
    • VP, Corporate Development & Reimbursement
    • Guardant Health
    • Alfred Slanetz, PhD
    • President & CEO
    • Geneius Biotechnology, Inc
    • Ipsita Smolinski, MBA, MPH
    • Managing Director
    • Capitol Street
    • Mark Soberman, MD, MBA, FACS
    • Chief Physician Executive
    • Monocacy Health Partners
    • David Spetzler, MS, MBA, PhD
    • President & CSO
    • Caris Life Sciences
    • Eric Sredzinski, PharmD
    • EVP, Clinical Affairs & Quality Assurance
    • Avella Specialty Pharmacy
    • Charles A. Stevens, JD, MBA
    • VP & Global Lead, Commercialization & Communications
    • ICON Access
    • President
    • MediMedia & Complete Healthcare Communications
    • ICONplc
    • Sean Tunis, MD, MSc
    • President & CEO
    • Center for Medical Technology Policy
    • Clorinda Walley
    • President
    • Good Days, Chronic Disease Fund
    • William (Bill) Winkenwerder Jr, MD
    • Chairman
    • CitiusTech
    • Former CEO
    • Highmark BCBS
    • Jedd Wolchok, MD, PhD
    • Director, Parker Institute for Cancer Immunotherapy
    • Memorial Sloan Kettering Cancer Center
    • William Yoon, PharmD, MBA
    • Executive Director & Head, US Medical Managed Markets & Strategic Alliances
    • Sandoz
    • Burt Zweigenhaft
    • Managing Partner, Upstream Partners
    • Co-Founder, AVBCC

Edward Abrahams, PhD

President, Personalized Medicine Coalition

Edward Abrahams is President of Personalized Medicine Coalition. Representing innovators, scientists, patients, providers, and payers, the Personalized Medicine Coalition promotes the understanding and adoption of personalized medicine concepts, services, and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 200 today.

Previously, he was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

He worked for 7 years for the US Congress, including as a legislative assistant to Senator Lloyd Bentsen, as an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as an American Association for the Advancement of Science Congressional Fellow for Representative Edward J. Markey.

The author of numerous researches, he serves on the Editorial Board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.

Maggie Adamski



Cheryl Allen, BS, PharmD, MBA

Vice President, Industry Relations, Diplomat

In her role as Vice President of Industry Relations at Diplomat Specialty Pharmacy, Cheryl Allen works with pharmaceutical manufacturers in finding partnerships and crafting healthcare solutions. Specifically, she helps to identify new opportunities within the pharmaceutical industry, then collaborates with manufacturers to design services and distribution solutions that support their patients’ journey.

Cheryl brings more than 25 years of industry experience, with work in independent and specialty pharmacies, as well as in managed care consulting and healthcare information technology. Before joining Diplomat Specialty Pharmacy in July 2011, Cheryl worked as Senior Director, Clinical Services, Sanovia Corporation, Philadelphia, PA, where she managed new product development and sales support. Prior to her tenure at Sanovia, she held roles with Priority Healthcare in Eddystone, PA, as Pharmacist-in-Charge, Oncology, and Lead Pharmacist, Pain Management. Cheryl also founded C. Allen & Associates, a firm focused on managed care consulting, and Eden Drug Company, an independent pharmacy.

Cheryl earned her Bachelor of Science in pharmacy at McWhorter School of Pharmacy, Samford University, Birmingham, AL, and her Master’s in business administration at Haub School of Business, Saint Joseph’s University, Philadelphia, PA, with a focus on pharmaceutical and healthcare marketing.

Rachel Anhorn, PharmD

Director, Payer Policy & Health Outcomes, Foundation Medicine

Regional Scientific Manager, Health Outcomes & Phamacoeconomics, Hospira

Rachel Anhorn is Director, Payer Policy & Health Outcomes, Payer Relations and Reimbursement Team, Foundation Medicine, Cambridge, MA, where she leads the development of US Health Economics and Outcomes Research initiatives and is focused on payer education about the unique clinical value of comprehensive genomic profiling. Her professional interests include helping shape healthcare policy to promote the value of oncology diagnostics and genomically matched precision treatment to improve outcomes and cost-effectiveness of cancer care for all stakeholders.

Previous to her role at Foundation Medicine, she worked as Medical Director, Biosimilars Group, Pfizer, Boston, MA; and at Boehringer Ingelheim, as Associate Director, Health Economics & Outcomes Research, where her team provided support for idiopathic pulmonary fibrosis, oncology, chronic obstructive pulmonary disease, diabetes, and atrial fibrillation, and as Medical Science Liaison, Metabolics, supporting the metabolic disease programs in endocrinology and nephrology.

Rachel received her education through Rutgers, The State University of New Jersey’s Postdoctoral Fellowship, her Bachelor’s in medical strategy and scientific communications, her PharmD at the University of Minnesota College of Pharmacy, Minneapolis, and her Bachelor of Science in biochemistry, at the University of Wisconsin-River Falls.

Sheila Arquette, RPh



Ray Bailey, RPh

Pharmacy Director, Florida Cancer Specialists

Ray Bailey is Pharmacy Director for Florida Cancer Specialists in Fort Myers. He is responsible for overseeing the operations of Florida Cancer Specialists’ Oncology Specialty Pharmacy, Rx To Go, which includes financial management, business development, new drug access, purchasing contracts, and overall formulary management. In 2010, he was promoted to this position 2 years after joining the company as the Pharmacy Manager.

Prior to his current role, he was General Manager of Walgreens/OptionCare of Southwest Florida. He was also Staff Pharmacist at Naples Community Hospital; owner of Pine Island Pharmacy; and President and Chief Executive Officer-Owner of OptionCare of Southwest Florida, a national franchise of home infusion pharmacy services.

He holds professional memberships and associations in the Community Oncology Alliance, an Advisory Board Member of the Community Oncology Pharmacy Alliance, an Advisory Board Member of the National Community Oncology Dispensing Association, the Hematology Oncology Pharmacist Association, and the Florida Pharmacy Association.

He earned his bachelor’s and graduate degrees in pharmacy from the University of Georgia.

Peter Bach, MD




Chair, Scientific Review Committee, Robert H. Lurie Comprehensive Cancer Center

Professor, Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University

Al Benson III is Professor of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, and Chair, Scientific Review Committee, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. He is Chair of the National Comprehensive Cancer Network (NCCN) Hepatobiliary Guidelines Panel and of the Colon, Rectal and Anal Panel, and a member of the Pancreatic Cancer and Neuroendocrine panels. In addition, he is Attending Physician at Northwestern Memorial Hospital, Staff Physician at Jesse Brown VA Medical Center, and Consultant to the Rehabilitation Institute of Chicago.

He earned his medical degree at the State University of New York at Buffalo following which he completed an Internal Medicine Residency at the University of Wisconsin Hospitals in Madison. He was Assistant Professor of Medicine at the University of Illinois and Co-Medical Director for the National Public Health Service in Champaign, IL. He then served as Clinical Oncology and Research Fellow at the University of Wisconsin Clinical Cancer Center, where he received an American Cancer Society Fellowship Award.

Active on numerous professional committees, he often serves as an officer. He is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award and has served on a number of committees. He has been a member of the Task Force on Quality of Cancer Care, co-chair of ASCO’s Colorectal Cancer Guidelines Subcommittee, the Stage II Colon Cancer Guidelines Panel, and the Guidelines Panel for use of Radiofrequency Ablation for Colorectal Cancer, for example. He also is immediate past chair of the ECOG-ACRIN Gastrointestinal Committee, current chair of the Data Monitoring Committee, and a member of the NCI Rectal/Anal Task Force. He is chair of the International Rare Cancers Initiative, Anal Cancer Committee, and a member of the Small Intestinal Cancer Committee. In addition, he is past president of the Illinois Medical Oncology Society, past president of the Association of Community Cancer Centers, executive committee member and past chair of the Board of Directors of NCCN, and a member of the Board of Directors of the NCCN Foundation. He is past president of the International Society of Gastrointestinal Oncology. He is a member of the Executive Committee of the Patient Advocate Foundation, the National Patient Advocate Foundation (president), and Scientific Advisory Committee of Friends of Cancer Research. Additionally, he is a medical advisory board member for Debbie’s Dream Foundation: Curing Stomach Cancer as well as Fight Colorectal Cancer.

He is on the editorial board of the Journal of the National Comprehensive Cancer Network, American Health & Drug Benefits, Personalized Medicine in Oncology, Journal of Comparative Effectiveness Research, and Gastrointestinal Cancer Research, among others.

His research is primarily in the areas of gastrointestinal cancer clinical trials, biologic therapies, phase 1 cancer clinical trials, health services research, and cancer guideline development. He has authored or co-authored numerous reports, reviews, and book chapters focusing on these topics. His research in biologics, cancer therapy, and cancer prevention has been awarded funding from a variety of sources, including the National Institutes of Health.

His most recent national awards include the NCCN Rodger Winn Award and the ACCC Outstanding Achievement in Clinical Research Award.

Kim Blackwell, MD



Douglas Bock, MBA

Partner, Archbow Consulting

Douglas Bock is a partner at Archbow Consulting, a strategic consulting practice for the pharmaceutical and biotechnology industry. He is frequently sought for his expertise in creating data-driven solutions to improve patient health outcomes worldwide. He advises clients on complex specialty product reimbursement, patient access programs, supply chain optimization, trade relations, and risk evaluation and mitigation strategies and risk management programs.

Douglas was also Co-Founder and Principal of a multinational firm dedicated to helping patients overcome the challenges of accessing pharmaceutical products worldwide.

He began his career working in operations at Merck Research Labs. From there he held a variety of sales, sales management, and marketing management positions at Merck and later at Solvay. He worked at Hoffmann-LaRoche in Licensing and US Commercial Operations. He has launch experience in more than 2 dozen therapeutic areas.

Douglas holds an Arts Baccalaureate in international relations from Colgate University, Hamilton, NY, and a Master of Business Administration from Yale University, New Haven, CT.

Jeffery Bockman, PhD, EVP



Rohit Borker, PhD



Brian Bourbeau, MBA, LSSBB

Associate Director, Business Metrics and Analysis, American Society of Clinical Oncology

Brian Bourbeau is Associate Director, Business Metrics and Analysis, within the Clinical Affairs Department, of the American Society of Clinical Oncology (ASCO). In this role, Brian oversees various practice health initiatives, including PracticeNET, a reporting and benchmarking service for ASCO members.

Prior to ASCO, he was Director, Practice Operations, Oncology Hematology Care, Cincinnati, OH, where he oversaw quality programs, managed care, and revenue cycle operations. Brian’s experience with alternative payment models include multiple Medicare, Medicaid, and commercial programs. His experience includes quality and financial management positions with The Ohio State University, University of Cincinnati Medical Center, and Lee Memorial Health System.

He holds a Master of Business Administration from Franklin University, Columbus, as well as certifications in Lean, Six Sigma, and Business Intelligence.

Joel Brill, MD



Barry Brooks, MD



Danielle Bubnis

Senior Director, Advocacy, Leukemia & Lymphoma Society

Danielle Bubnis currently serves as Senior Director of Advocacy for the Leukemia & Lymphoma Society, Office of Public Policy. In this role, Danielle provides strategic leadership to the organization’s advocacy program, and manages a national, field-based team, developing advocacy initiatives to advance policies that support access to care for patients. Prior to this role, she worked extensively on issue-based advocacy campaigns in the mid-Atlantic and northeast regions of the United States, providing strategy and leadership to coalitions of patient advocacy groups, healthcare professionals, industry partners, and professional organizations. Her work also included developing and implementing volunteer-based advocacy networks across these regions.

Danielle is a licensed social worker and has spent her entire professional career supporting patients and their families living with a diagnosis of cancer. Prior to her work with the Office of Public Policy, Danielle served as Patient Services Manager at the Leukemia & Lymphoma Society, offering assessment and overall psychosocial support to patients with blood cancer and their family members throughout their cancer journey. In this role, she developed and coordinated patient support programs, which included family support groups, financial assistance, peer-to-peer support, and educational sessions. Before joining the Leukemia & Lymphoma Society team in central Pennsylvania as Patient Services Manager, she served as Oncology Social Worker at the Janet Weis Children’s Hospital in Danville, PA.

Danielle graduated from Dickinson College, Carlisle, PA, with a Bachelor of Science in psychology and mathematics and earned her Master’s degree in social work from Marywood University, Scranton, PA. She is currently a licensed social worker in the state of Pennsylvania.

Randy Burkholder



Rob Butcher



Virginia Calega, MD, MBA, FACP



Nick Calla

Vice President, Industry Relations, Cardinal Health Specialty Solutions

President, Specialty Pharmacy Certification Board

Nick Calla is Vice President, Industry Relations, Cardinal Health Specialty Solutions, Pittsburgh, PA, and is responsible for the development of relationships in the manufacturer community as it pertains to products within their specialty portfolio. Prior to Cardinal Health, Nick was Vice President, Trade Relations, Community Specialty Pharmacy Network, where he was responsible for business development, relationship maintenance with manufacturers around the country, and the clinical programs designed to support those products. He also performed the same duties for Walgreens Specialty Pharmacy.

Prior to working at Walgreens, he was Director, Clinical Programs and Network Administration, Eckerd Health Services, and President and General Manager, Oncology Pathways, a group purchasing organization founded by the University of Pittsburgh Medical Center Hillman Cancer Center and Medmark Specialty Pharmacy. He has experience working with the pharmaceutical manufacturing and the retail pharmacy community and has also participated in several pharmacy and therapeutics committees.

He is a member of the National Association of Chain Drug Stores, Academy of Managed Care Pharmacy, and the National Association of Specialty Pharmacy. Currently, Nick is the President of the Specialty Pharmacy Certification Board. His expertise is in the areas of compliance, disease management, intervention programs, and negotiations.

He received his Bachelor’s degree in pharmacy from the University of Pittsburgh, PA, and received a Juris Doctorate from Duquesne University, Pittsburgh. In addition, he has completed fellowship programs at the University of Pennsylvania, Philadelphia; University of Southern California, Los Angeles; and Harvard University, Cambridge, MA.

Neil Canavan, MSc

Scientific Advisor, Solebury Trout

Neil Canavan is a veteran science journalist with more than 20 years of experience reporting on the technologies of drug development. He joined the Solebury Trout team as Scientific Advisor in 2014, where he recruits key opinion leaders in the immuno-oncology space to educate healthcare/biotechnology investors on this revolutionary, rapidly evolving field. After 2 years of organizing such symposia, it became clear that a wider educational effort was warranted. The culmination of that effort is Canavan’s new book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer.

Kevin Cast

Partner, Archbow Consulting

Kevin Cast is Partner, Archbow Consulting, Windermere, FL. His career in the pharmaceutical and biotech industries spans 3 decades. He has held sales and trade positions at Ciba-Geigy and Serono, and has managed specialty pharmacy accounts, distribution, and historically underutilized business development at Express Scripts as Vice President, Pharma Business Development.

Kevin enjoys leveraging this experience for Archbow clients by developing unique strategies to maximize the current supply/service chain, while considering trends that predict future needs.

He holds a Bachelor of Liberal Arts in biology from Illinois Wesleyan University, and a Master’s degree in botany from Oklahoma State University, Stillwater.

Once an EMT, he gets his money’s worth out of his botany degree by tinkering in his garden. He “botanizes at 65 miles per hour” on the long drives he and his wife of 30 years take to visit their 2 children. He’s proud that both of his kids have chosen careers in healthcare. His son is a PharmD, and his daughter is styding to become a speech pathologist.

Nicole Caswell



Bob Charles, BS, MBA

Principal & Founder, The GeneriSys Company

Bob Charles is a senior executive in the biotech distribution industry, with specific expertise in a payer-centric pharmacy model. Currently, Bob serves as Principal and Founder of GeneriSys, which is a global pharmaceutical channel manager with the mission to promote “Generics for America; Brands for the World.” Clients include Target, Humana, Prime Therapeutics, Fred’s Stores, PharMerica, Merck, Shire, and many others. In addition, he was Co-Founder and majority shareholder in Axon, a technology platform that connects physicians, payers, pharmacies, and other healthcare providers to automate the prior authorization transaction.

Previously, he was Staff Vice President at WellPoint Specialty Pharmacy, where he planned and implemented business development strategies that grew the start-up division to a more than $1 billion revenue base within 3 years.

Bob has worked in senior leadership positions at Priority Healthcare (Senior Director, Oncology Services), OptionCare (Vice President, Sales and Marketing), and Express Scripts Infusion and Specialty Services (Regional Director), consistently achieving improvements to clinical and financial outcomes.

In these roles, he has maintained deep relationships with pharmaceutical manufacturers, both brand and generic manufacturers. He serves on a variety of pharmaceutical ad boards, including Merck Bioventures, Biogen-Idec, Genzyme, GlaxoSmithKline, Genentech, Dr. Reddy Labs, and Aurobindo.

Finally, he serves on the Board of Directors for AOAExcel, a for-profit division of the American Optometry Association. In this role, he helped divest an information technology segment in a multimillion-dollar transaction. Continued work focuses on deploying value-added services for optometry practices, such as a group purchasing organization, HIPAA compliance, and practice transitions solutions.

Anthony Coletta, MD, MBA



Charlie Coltman



George William Daneker Jr, MD

Corporate Chief Medical Officer, Cancer Treatment Centers of America

George William Daneker Jr brings more than 30 years of surgical experience and clinical leadership in his position as Corporate Chief Medical Officer at Cancer Treatment Centers of America, where he helps to set the clinical culture for the enterprise and leads clinical program development, particularly around issues of clinical consistency and excellence in patient care. He is actively involved in the business transformation process, including the development of future business platforms.

His career in surgical oncology has included the care of patients with intra-abdominal cancers, skin and soft tissue cancers, and breast cancer. He is skilled at advanced procedures, such as laparoscopic surgery and robotics. He joined the Cancer Treatment Centers of America in 2011 as Clinical Lead in Atlanta, where his roles multiplied as Chief of Staff, Chief of Surgery, Chief of Nutritional Support, and Research Director.

Prior to his current role, he served as Chief of General Surgery, Director of Surgical Oncology, Oncology Research, and Robotic General Surgery at St. Joseph’s Hospital (now Emory Healthcare) in Atlanta. There, he initiated a research collaboration with the Georgia Institute of Technology and instituted the multidisciplinary tumor board for gastrointestinal oncology. He was Founding Partner of North Atlanta Surgical Association, a 20+ surgeon professional corporation, as well as a Founding Partner of CancerData.com and Vice President of Outpatient Surgical Management.

He has authored many journal articles, abstracts, and book chapters on cell biology, tumor biology, and surgical oncology. He co-edited The Mont Reid Handbook: The University of Cincinnati Surgical Manual, 2nd edition, in 1990 and has been a guest reviewer for The Annals of Surgical Oncology.

He has received numerous acknowledgments for his work, ranging from the Armand Hammer International Travel Award from the Society of Surgical Oncology, the Top Doctors for Cancer by Newsweek magazine since 2015, Top Cancer Doctors by Castle Connolly, and has been named by U.S. News & World Report in the top 1% of surgeons in the United States.

He graduated cum laude with a Bachelor degree in biology from Loyola College of Baltimore in Maryland, and earned a medical degree with honors at the University of Maryland School of Medicine in Baltimore. He completed his internship and residency in general surgery at the University of Cincinnati Medical Center, and completed his clinical and research fellowships at Harvard Medical School and The University of Texas M.D. Anderson Cancer Center.

Brian DeBusk, PhD, MBA



Michael DeLeo, MD



Atul Dhir, MD, DPhil

Chief Executive Officer, New Century Health

Atul Dhir is Chief Executive Officer of New Century Health. He is a physician and scientist with more than 25 years of leadership experience in building and leading innovative healthcare companies.

Before joining New Century Health, he was Chief Executive Officer of BiPar Sciences, a cancer-focused biotechnology subsidiary of Sanofi-Aventis. Prior to BiPar Sciences, he was at US Oncology (now McKesson Specialty Health), one of the largest providers of cancer care in the United States. During his time with US Oncology, he led several businesses, including serving as President of the company’s Cancer Research Group. He has also held senior positions in the healthcare division of Monsanto Company and as a consultant at McKinsey & Company.

He received his medical degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his doctorate of philosophy in medicine from the University of Oxford, UK, where he studied as a Rhodes Scholar.

Luis Diaz, MD

Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center

Luis Diaz is the Division Head, Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center (MSKCC), where he specializes in the treatment of advanced pancreatic and colorectal cancers and directs the Precision Prevention & Interception Program. Prior to his role at MSKCC, he was a member of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins and directed the Swim Across America Lab. He is also founder of several entities that focus on genomic analyses of cancers, including Inostics, PapGene, and Personal Genome Diagnostics (PGDx).

He has undergraduate and medical degrees from the University of Michigan and completed residency training at the Osler Medical Service at Johns Hopkins and medical oncology training at the Sidney Kimmel Cancer Center at Johns Hopkins.

His pioneering work has involved the clinical development of tumor-derived DNA as a biomarker for cancer screening, early detection, monitoring, and measurement of early residual disease. The basis of this work is based on the well-accepted premise that cancer is defined by a discrete set of genetic alterations. This approach combines a next-generation genomic sequencing with novel digital techniques to count tumor-derived DNA fragments in complex mixtures of DNA. The mutations found in cancers are never found in normal cell populations and detection of these mutations therefore confers exquisite specificity to the assay. Accordingly, he demonstrated that the level of mutations in the circulation, also known as circulating tumor DNA (ctDNA), tracked with fluctuations in tumor burden in patients undergoing resective surgery for colorectal cancer. Most striking is the ability of ctDNA to accurately predict recurrence after surgery and monitor patients with undetectable CEA levels. This novel biomarker is based on personalized genomics that provides a “viral load” equivalent for patients with solid tumors. The preliminary studies served as the basis for his most recent invention, the “molecular pap smear,” which is a promising approach for the early detection of ovarian and endometrial cancers.

He has also harnessed the power of cancer mutations as potent antigens and championed the use of checkpoint inhibitors in the treatment of patients with tumors with high mutational burden. His landmark proof of this principle studies using PD-1 blockade in patients with mismatch repair deficiency and showing dramatic and potentially curative responses in more than 50% of metastatic patients, which resulted in the first historic FDA approval of a cancer treatment for any solid tumor in adults and children with a specific genetic feature.

He is a member of the groups that received the 2013 AACR Team Science Award for Pancreatic Cancer Sequencing, the 2014 AACR Team Science Award for Malignant Brain Tumor, and the 2017 AACR Team Science Award for Liquid Biopsies. He is also the leader of the 2017 SU2C Colon Cancer Dream Team. He is an elected member of the American Society for Clinical Investigation. In addition, his work has been highlighted in several scientific and lay media outlets, including The Diane Rehm Show, New York Times, NPR, CNN, and NBC nightly news.

Mikael Dolstein, MD, PhD



Christian Downs, JD, MHA



Eric Dozier, BS, MBA



Amy DuRoss, MBA

Co-Founder and Chief Executive Officer, Vineti

Amy DuRoss is Co-Founder and Chief Executive Officer of Vineti, which creates next-generation technology to drive and scale high-value medicine. Before co-founding Vineti, Amy was the Managing Director for GE Ventures, where she focused on GE Healthcare’s new business creation, Healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was Co-Founder and Executive Director of Proposition 71, California’s $3-billion stem-cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency.

Amy holds a Masters in Business Administration and an MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute.

Ravinder Dhawan, PhD

Vice President and Head, Oncology Product Line, Center for Observational and Real World Evidence, Merck

Ravinder Dhawan is Vice President and Head, Oncology Product Line, Center for Observational and Real World Evidence, at Merck, and has responsibility for generating evidence to support value proposition for Merck’s oncology products throughout their lifecycle. He has more than 20 years of experience in outcomes research, market access, and pharmaceutical pricing.

Prior to joining Merck, he served as Head of the Oncology Outcomes Group at Sanofi and was Head of Global Market Access in Oncology and Metabolics at Johnson & Johnson Pharmaceuticals for more than 10 years, and led the Outcomes Research Group at Roche prior to that.

Earlier in his career, he taught health economics at the University of Western Ontario in Canada and the University of Connecticut in the United States. During his career, he has developed wealth of experience in dealing with reimbursement and access issues with various health technology assessment agencies around the globe.

He has authored more than 70 abstracts, posters, and publications in health economics and outcomes research.

Richard Evans, DVM

Co-Founder and Head of Healthcare Practice, Sector & Sovereign Research

Richard Evans is Co-Founder and Head of Healthcare Practice of Sector & Sovereign Research Health. As a senior executive in the pharmaceuticals industry, his responsibilities ranged from corporate strategy to the pricing and distribution of the company’s products. Prior to founding SSR Health, he was the author of “Health and Capital,” which was published in August 2009. He was also a Senior Analyst at Sanford C. Bernstein and was ranked #1 by Bloomberg and Institutional Investor for his US pharmaceuticals coverage, and was ranked in the top 20 analysts worldwide. He was previously also Vice President, Business Policy and Account Management, at Roche.

He graduated in 1998 with his Doctor of Veterinary Medicine, specializing in large animals, food animals, and equine surgery, at the College of Veterinary Medicine, North Carolina State University. In 1991, he received his Masters of Public and Private Management from Yale University.

Matt Farber, MS



Brenton Fargnoli, MD



Jonathan Fassberg

Co-Chief Executive Officer, Solebury Trout

Jonathan Fassberg is Co-Chief Executive Officer, Solebury Trout, and a visionary entrepreneur who recognized early in his career that small-cap biotechnology companies were underserved in an investor relations capacity. To fill this void, he founded The Trout Group in 1996 and grew it to become the leading investor relations firm in the life sciences industry. Trout has served more than 750 public and private companies domestically and internationally. In 2017, Trout was acquired by Solebury Communications, and the combined firm became known as Solebury Trout.

Highlights of his career include guiding Pharmasset, Pharmacyclics, and GW Pharma from inception to initial public offerings to product launches and ultimate acquisitions. Today, he focuses on client service and outreach to investors to build stable shareholder bases for his clients.

Prior to Trout’s founding, he was a sell-side analyst at a healthcare-focused investment bank. Before his career on Wall Street, Jonathan spent 4 years at DuPont Pharma in various sales and marketing positions.

He has been an active member of Young Presidents Organization since joining the Manhattan Chapter in 2007 and is currently serving as Chapter Chair. He also sits on the Board of Directors for the Carolina Center for Jewish Studies at the University of North Carolina.

Jonathan holds a Bachelor of Science in biology and chemistry from the University of North Carolina–Chapel Hill and a Master in Business Administration in finance from New York University’s Stern School of Business. He also holds Series 7, 24, 79 and 63 securities licenses.

A. Mark Fendrick, MD



Christine Ferro, CHFP



Anthony Fiori

Managing Director, Manatt Health

Anthony Fiori is Managing Director of Manatt Health in New York City. A recognized authority on health plan regulatory and financial issues, Anthony advises healthcare industry clients on regulations and strategy, analyzes policies, and manages projects. Medicaid and Medicaid managed care, the Affordable Care Act, healthcare financing, and delivery system reform are his areas of focus. He is also a recognized consultant on Federal Medicaid Pharmaceutical Policy.

He works with managed care organizations, hospitals, long-term care organizations, state Medicaid agencies, pharmaceutical manufacturers, and trade associations, bringing depth and perspective to public health insurance programs.

Currently, he leads a coalition of nonprofit Medicaid managed care plans in New York and represents these plans before the New York State Department of Health and other regulatory and legislative bodies on rate development, payment and delivery system reform, managed care expansion, health homes, and quality measurement. He also advises state hospitals and plans implementing the Affordable Care Act and Medicaid redesign—including the expansion of Medicaid managed care—in New York, Alabama, Oregon, North Carolina, and other states. In addition, he works for and advises pharmaceutical manufacturers on the implications of federal and state Medicaid policies with regard to their business.

Before joining Manatt, he worked for the New York City Economic Development Corp, where he structured debt for nonprofits, including a number of healthcare-related organizations. He also was a consultant to the Henry J. Kaiser Family Foundation, where he co-authored a report on the health insurance market and its impact on employer coverage.

As a policy advisor for the San Diego Regional Chamber of Commerce, he led a campaign to educate community and business leaders on the importance of a comprehensive and affordable healthcare network.

C. Lyn Fitzgerald

Senior Vice President, US & Global Development, National Comprehensive Cancer Network

C. Lyn Fitzgerald is Senior Vice President, US & Global Development, National Comprehensive Cancer Network (NCCN). In this role, she is charged with the development of US and International business strategies. She serves as the key contact for the industry and oversees the NCCN Corporate Council and all permissions and licensing of NCCN content for commercial use. In addition, she provides oversight of NCCN Business Development, NCCN Business Insights, NCCN International Program, NCCN Policy Program, NCCN Payer and Employer Outreach, NCCN Communications & Marketing functions, and the NCCN Academy for Excellence & Leadership in Oncology School of Pharmaceutical & Biotech Business.

Prior to joining NCCN, she was a member of the Business Development team at the Nemours/Alfred I. DuPont Hospital for Children, where she worked to develop and advance communication strategies for building and maintaining provider relationships. She was responsible for professional relations, including physician advocacy, and served as liaison to Nemours partner hospitals and to community practices, including providing educational programming and support.

From 1995 to 2001, she served as Key Specialty Senior Representative at Schering-Plough Pharmaceuticals. A 2-time Temple University graduate, earning a Bachelor of Business Administration in economics from the Fox School of Business and a Master of Journalism from the School of Communications. She is a published author of multiple articles on health and healthcare policy.

Michael Fitzgibbons



William Flood, MD, MSc



Liz Fowler, PhD



Elizabeth Franklin, LGSW, ACSW

Executive Director, Cancer Policy Institute, Cancer Support Community

Elizabeth Franklin is Executive Director, Cancer Policy Institute (CPI) at the Cancer Support Community (CSC). CSC is the largest provider of social and emotional support services for patients with cancer and their loved ones in the United States. The CPI brings together patient advocates and policy experts to ensure that the voices of patients with cancer and their loved ones play a central role in federal and state legislative, regulatory, and executive policymaking. The CPI works in partnership with patient advocates, the CSC affiliate network, and numerous allied healthcare and oncology organizations to work toward a future where 15.5 million cancer survivors have access to comprehensive, high-quality, timely, and affordable medical, social, and emotional care. Elizabeth is responsible for all aspects of the CPI, including legislative, regulatory, policy, and research priorities as well as operations, fundraising, and management. She was previously Senior Director of Policy and Advocacy at CSC.

Elizabeth was formerly Director of Policy and Engagement at The George Washington University Cancer Institute, where she worked at the macro level, developing and implementing the Institute’s policy agenda; and at the micro level, working with the patient-centered care team to ensure that all patients had access to high-quality, timely cancer care. Previously, she was Senior Director of Policy and Advocacy with the Prevent Cancer Foundation as well as Special Assistant to the Chief Executive Officer at the headquarters of the National Association of Social Workers.

She is a recognized author and speaker. Her articles have appeared in publications such as the Journal of Cancer Education, Health and Social Work, and CONQUER: the patient voice magazine. She has co-authored 2 books on nonprofit leadership and co-edited 2 social work texts. In addition, she is a member of various organizations and coalitions, including the National Association of Social Workers (where she serves as President of the DC Chapter), Association of Oncology Social Work (where she serves on the Advocacy Committee), Academy of Oncology Nurse & Patient Navigators (where she serves on the Leadership Council and as Chair of the Policy and Advocacy Committee), Alliance for Quality Psychosocial Cancer Care, and Society for Social Work and Research.

Currently a doctoral candidate at the University of Maryland School of Social Work, she is focusing her dissertation on the ways in which patients define value in the cancer care system and how those definitions can be incorporated into public policy and clinical practice. She obtained her Masters in social work from the University of Illinois at Chicago and her Bachelor’s degree in social work from the University of Kentucky. She is a Licensed Graduate Social Worker in the District of Columbia and a member of the Academy of Certified Social Workers.

Bedrick Gadea, PhD



Rowdy Gaines

Speaker, Swim Across America

Vice President, Aquatics, Central Florida YMCA

Throughout the 1980s, Rowdy Gaines was the fastest swimmer on the planet, and his world records confirmed his place in swimming history when he set world records in the 100- and 200-meter freestyles at the Olympic Games in Moscow, Russia. He has been induced into the US Olympic Hall of Fame and the International Swimming Hall of Fame.

In 1991, he was diagnosed with Guillain-Barre syndrome, an autoimmune virus that attacks the nervous system, and he was paralyzed for more than 2 weeks. He fought back, overcame the disease, and 1 year later went to the World Masters Championships and won the 50- and 100-meter freestyle events.

He works with many charitable organizations, including the USA Swimming Foundation; Swim Across America, which benefits research for cancer; and the Special Olympics. He mentors kids and spreads the message that championship comes not from the outside, but from the inside, and dreams can come true if you believe in yourself. He is a highly sought after motivational speaker and shares his inspiring story of perseverance.

Jude Gallagher

Founder and Managing Partner, Channel Health Advisors

Jude Gallagher is a strategic leader with more than 30 years of healthcare experience across a spectrum of provider and payer systems. She is Founder and Managing Partner of Channel Health Advisors in Louisville, KY. As a Certified Physician Assistant with a Master’s in Business Administration, her expertise and leadership within direct patient care, program design, hospital administration, and managed care produced novel clinical strategy and program designs, quality and operational improvements, resulting in moving complex problems to operational success.

In her previous role as Director, Complex Care Clinical Strategy, at Humana, Jude designed and implemented a broad range of programming, including direct-to-consumer self-management programs and provider-facing quality and value-based designs. She participated in “buy versus build” decision- making as well as vendor partner selection and implementation of national programs. She led advanced care planning strategy and introduced intervention designs based on stages of health, from the very well to seriously ill adult. Before working at Humana, she was Vice President, Clinical Operations, Quality Oncology, where she provided strategic oversight and direction of the Utilization Management, Care Management, and Quality Programs. This included leading implementation of 50 contractual relationships with national and regionally based payers and employer groups.

Jude brings her passion for supporting each individual’s voice in healthcare decision-making and improving navigability of care delivery. She shares her talents through mentoring of others and serving on the boards of local cancer nonprofits.

Lisa Gill, CPA

Managing Director, Senior Analyst, US Healthcare Technology and Distribution Equity Research, J.P. Morgan

Lisa Gill is Managing Director and Head of US Healthcare Technology and Distribution Equity Research for JP Morgan in New York City for 16 years. She has been a member of the highly regarded JP Morgan Healthcare research team for 20 years, has been ranked #1 by Institutional Investor for the past 8 years, and has consistently been ranked in the top 3 by Institutional Investor and external polls since 2005. In her current position, she is responsible for coverage of 17 companies within healthcare services, including healthcare distribution, pharmacy benefit management, drug retail, healthcare information technology, clinical labs, and institutional pharmacy sectors.

She is a certified public accountant and started her career with Ernst & Young’s audit group, specializing in healthcare facilities. She then worked at Coopers & Lybrand’s healthcare services consulting group, where her main focus was on physician and long-term care reimbursement. Prior to joining JP Morgan, she was Director of Development at Health Partners, where she acquired physician practices in New York City.

She is currently a member of the Investment Bank Women’s Network and a leading member on the Mentoring Committee of Women in Research.

Robert Goldberg, PhD

Co-Founder and Vice President, Center for Medicine in the Public Interest

Robert Goldberg is Co-Founder and Vice President of the Center for Medicine in the Public Interest (CPMI), a nonprofit organization that advocates for consumer access to medical innovation, better health information, and personalized healthcare. He is also Founder of CMPI’s Value of Medical Innovation initiative that promotes awareness of the value of medical progress.

Prior to founding CMPI, he was Director of the Manhattan Institute’s Center for Medical Progress and Chairman of its 21st Century FDA Task Force that examined the impact of the FDA’s Critical Path Initiative on drug development and personalized medicine.

His academic research focuses on the value of personalized medicine and medical innovation to longevity, economic growth, and well-being. He is the author of Tabloid Medicine: How the Internet Is Being Used to Hijack Medical Science for Fear and Profit (Kaplan, 2011), and writes op-eds and articles for a wide variety of media outlets, including Scientific American.

Patricia Goldsmith

Chief Executive Officer, CancerCare

Patricia Goldsmith is Chief Executive Officer of CancerCare since 2014, overseeing the vision and direction of the organization. Patricia brings more than 20 years of nonprofit management and strategic planning experience to the role, and has a proven record of success in hospital and physician academic organizations, as well as nongovernmental healthcare organizations.

She previously served as Executive Vice President and Chief Operating Officer at the National Comprehensive Cancer Network (NCCN). In this role, she was responsible for the overall operations of the NCCN. She reported directly to the Chief Executive Officer and provided oversight of the functions of the NCCN Oncology Outcomes Database, NCCN Oncology Research Program, Finance, US & Global Business Development, Marketing and Communications, Public Affairs, Professional Publications, Best Practices, Analytics, Research & Consulting, Conferences and Meeting Planning, Media Programs, Continuing Medical Education, Grants, and Information Technology. In addition, she was responsible for public policy initiatives at the federal level and national initiatives related to payers and employers, including the education related to these constituencies. Patricia was also responsible for the NCCN Foundation, established as the philanthropic affiliate of NCCN to embrace the NCCN mission of improving the quality and effectiveness of care provided to patients with cancer.

She formerly served as Vice President for Institutional Development, Public Affairs, and Marketing at the Moffitt Cancer Center in Tampa, FL, a NCCN Member Institution. There, she oversaw the Moffitt Cancer Center’s Foundation, Public Relations, Marketing, and Business Development functions in addition to fundraising initiatives. Before joining Moffitt, she developed and directed all managed care activities for the University of South Florida College of Medicine.

A frequent speaker at national meetings and symposia, she was chosen by US Representative Bill McCollum (R-FL) in 2003 to join a panel of 100 thought leaders representing every stakeholder interest in healthcare. This unique effort focused on building consensus about what structural changes could be made in our nation’s healthcare delivery system to assure quality healthcare for future generations. Recently, she participated as a faculty panel member at Bristol-Myers Squibb’s 2015 Market Access Summit, focusing on the patient experience from diagnosis, through treatment, and beyond, and at the Fifth Annual Association for Value-Based Cancer Care Conference, where her session focused on patient engagement and patient assistance. Prior to these conferences, she participated as a speaker at the 16th Annual Patient Assistance & Access Programs Meeting, her session, entitled “Cross-Functional Strategies for Advocacy Relationship Development,” and as a panel participant at the Turning the Tide Against Cancer Through Sustained Medical Innovation Conference, her session, entitled “Addressing the Value and Cost of Cancer Care.”

She has studied at the Pennsylvania State University, the University of Missouri Bloch School of Business, and the Harvard School of Public Health. She was a winner of the 1999 Distinguished Women in Business Award sponsored by the Business Journal of Tampa Bay and also was named the 1999 Leukemia Society Woman of the Year, an award based on her philanthropic efforts on behalf of The Leukemia Society.

Scott Gottlieb, MD



Bruce Gould, MD



J. Lance Grady



Robert Green, MD

Senior Vice President, Clinical Oncology, Flatiron Health

Robert Green is the Senior Vice President, Clinical Oncology, Flatiron Health, New York, NY, and practicing medical oncologist. In his role as Senior Vice President, he oversees the team responsible for clinical development of OncoEMR, the industry’s leading electronic medical record software for medical oncology, as well as Flatiron’s other provider-facing software products, and clinical content development.

Prior to joining Flatiron Health, he was Managing Partner, Palm Beach Cancer Institute, FL, and helped lead its merger with Florida Cancer Specialists in 2013. He continues to see patients in West Palm Beach, FL, at Florida Cancer Specialists on a part-time basis. Previous to that, he served as Chief Medical Officer at Cancer Clinics of Excellence, where he led initiatives on molecularly based clinical trials, integrating genomic testing into community practices, alternative payment models, and data analytics. He currently serves on the board of the Community Oncology Alliance.

He received his undergraduate and medical degrees from Duke University and a Master’s of Science degree in clinical epidemiology and biostatistics from the University of Pennsylvania.

Lindsay Greenleaf



Melinda Haren, RN

Senior Director, Access Strategies, Zitter Health Insights

Melinda Haren joined Zitter Health Insights in 2004 and is currently Senior Director, Access Strategies. She has been part of the development of the majority of Zitter Health Insights’ syndicated product lines. Melinda is an acknowledged expert in prior authorization and payer coverage strategy. Her current role is in helping our clients understand the payer market and how it may impact their strategies. She has authored one book and scores of articles on healthcare and speaks frequently at national meetings.

Prior to Zitter Health Insights, she worked as Disease Manager at Highmark, where she designed and implemented a disease management program for approximately 20,000 members. The program increased member satisfaction and decreased the opt-out rate to less than 1% and saved more than $80,000 a year. The program was recognized by the National Committee for Quality Assurance in its 2002 Quality Compass.

She earned her registered nurse license from Harrisburg Area Community College and her Bachelor of Arts from Thomas Edison College of New Jersey.

Lisa Harrison, RPh

Vice President, Practice Business Solutions, Specialty Physician Services, AmerisourceBergen

Lisa Harrison is Vice President, Practice Business Solutions for AmerisourceBergen’s Specialty Physician Services. She oversees solutions to enhance business performance for community practices and empower patient care in her current role. Lisa also leads the Specialty Oncology Network advisory panel for the organization. Members of the panel include pharmacy directors, physicians, and administrators.

Lisa was formerly the Director of Pharmacy Services for ION Solutions, an AmerisourceBergen company, where she led the Clinical Practice Consultant team. In this role, she and the Clinical Practice Consultant team supported the development and implementation of the Specialty Oncology Network Physician Dispensing and Retail Pharmacy clients. She brings 12 years of experience in oncology, with 8 years spent in a large oncology practice and 4 additional years on the provider side of the industry.

She earned her Bachelor of Science in chemistry and business from Judson College followed by a Bachelor of Science in pharmacy from Auburn University.

Edward Hensley

Founder and Chief Commercial Officer, AssistRx

In 2010, Edward Hensley founded AssistRx, a technology-enabled pharmaceutical solutions company that focuses on creating digital solutions for patients prescribed specialty medications. He is also on the Board of Directors for etectRx and the United Arts of Central Florida. He has spent his entire career in healthcare, focused mainly in the specialty segment.

He was part of the original management team at CuraScript, serving as Vice President of Pharmaceutical Relations. After successfully transitioning his role after the Express Scripts transaction in 2004, he went on to establish Advanced Care Scripts in fall 2005. After experiencing explosive growth when the Medicare Part D benefit was introduced, in late 2008 he sold and transitioned the business to Omnicare, which is now part of CVS Health.

He holds a Bachelor of Arts degree in English from The University of Texas at Austin and a Master’s in Business Administration from The Jones School of Business at Rice University.

Tara Herington

Vice President, Sonexus Access and Patient Support, Cardinal Health Specialty Solutions

Tara Herington is Vice President, Sonexus Access and Patient Support, Cardinal Health Specialty Solutions, where she leads her team to provide solutions beyond traditional HUB services to help patients and providers access specialty products with unprecedented speed, efficiency, and empathy.

Tara is a seasoned biotechnology and operations executive with more than 20 years of experience, and has successfully built organizations and programs for small, mid-sized, and large pharmaceutical manufacturers. She enjoys working in concert with manufacturers to deliver outstanding patient support programs that deliver patient-centered results.

Prior to her current role with Cardinal Health, she was responsible for leading patient support programs for pharmaceutical companies ranging from orphan disease medications to blockbuster products. She also has experience in field reimbursement, training, payer strategy, and quality assurance. She maintains her registered nurse licensure in the state of Texas.

Jennifer Hinkel, MPH



Brad Hirsch, MD



Axel Hoos, MD, PhD



Kevin Host, PharmD



Clifford Hudis, MD, FACP, FASCO



Louis Jacques, MD

Chief Clinical Officer, ADVI Health LLC

Louis Jacques is Chief Clinical Officer at ADVI Health LLC, a healthcare advisory services firm, where he is also a partner. He leads preclinical and clinical development work on postmarket coverage. He has a distinguished career in government service and medicine, which includes his experience as Director of Coverage & Analysis and Division Director of Items and Devices for the Centers for Medicare & Medicaid Services (CMS), where he led the collaboration with the US Food and Drug Administration in the Entrepreneurs in Residence Program.

While working for CMS, he managed the Medicare Fee-for-Service Coverage Policy development on technologies as diverse as molecular diagnostic testing, implanted cardiac devices, advanced imaging, chemotherapeutics, wound care, and screening and preventive services.

Before joining CMS in 2003, he served as Associate Dean for Curriculum at Georgetown University School of Medicine, where he also saw patients at the Lombardi Cancer Center in his practice of hospice and palliative medicine. He is passionate about change and innovation and has coauthored more than 60 Medicare Coverage Determinations and developed program oversight of the Local Coverage Determination process.

Paul Jardina, MBA

President and Chief Executive Officer, Onco360® Oncology Pharmacy Solutions

Paul Jardina is President and Chief Executive Officer of Onco360 Oncology Pharmacy Solutions, where his overall responsibility is the strategic direction of the company and execution of its plans. He has led the continued development of the company’s clinical pharmacy services focused on providing evidence-based, high-touch services to patients and oncologists in the community-based, academic medical center, and hospital setting. Paul has more than 23 years of experience in the healthcare industry, with the majority of that time dedicated to oncology.

Prior to joining Onco360, he served as President and Chief Executive Officer of U.S. Physiatry, a physician services company focused on transitional care in the post-acute continuum. Over the course of the previous 10 years, he served in various leadership positions for US Oncology (now part of McKesson Specialty Health), including leading the oncology specialty pharmacy, drug distribution, radiation and imaging, and other business lines for the company.

He holds a Bachelor of Science in industrial engineering from Georgia Tech and a Master in Business Administration from Emory University.

Danelle Johnston, MSN, RN, ONN-CG, OCN

Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives, The Lynx Group

Danelle Johnston is Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives for The Lynx Group. In this role, she oversees the strategic and operational responsibilities of staff, programs, and expansion of the Academy of Oncology Nurse & Patient Navigators (AONN+) as well as the execution of its mission. She is instrumental in supporting the many committee activities within AONN+, exploring and nurturing partnerships with other organizations in clinical and oncology arenas, and providing key clinical and professional insight that will help AONN+ enhance its sponsorships and services.

With more than 24 years of experience holding a variety of positions and a diverse and progressive oncology nursing background, Danelle is recognized as a national leader in oncology nurse navigation and in innovative community outreach and education focused on improving clinical care coordination and supporting the growth of others in the profession. Providing the most recent evidence of this was her appointment to the Biden Cancer Initiative Advisory Committee.

As a longtime AONN+ member, Danelle serves on the Academy’s Leadership Council and is Co-Chair of its Quality Metrics Task Force. Her leadership has helped the task force to identify and document 35 standardized evidence-based metrics for navigation that concentrate on return on investment, patient experience, and clinical outcomes. For her efforts, AONN+ recognized Danelle with its “Exceptional Research in Navigation Award.”

She earned a Bachelors from Azusa Pacific University and a Masters in nursing, with an emphasis on leadership and management, from Western Governors University. She is a member of the American Cancer Society’s National Navigation Roundtable: Evidence-Based Promising Practices Committee.

Anna Kaltenboeck



John Kelton, PharmD

US Medical Director, Biosimilars Inflammation, Pfizer

John Kelton is US Medical Director, Biosimilars Inflammation for Pfizer and has more than 25 years of experience in the pharmaceutical industry. Since 2000, John’s focus has been on medical affairs, serving in a variety of capacities, including management of medical communications and training, medical review, medical education, medical science liaisons, and investigator-initiated trials.

For the past 5 years, John has been actively involved in biosimilar development and educational efforts in the United States and Europe. He has collaborated with biosimilars experts who have expertise ranging from bench to bedside in nephrology, inflammation, and oncology in order to capture and communicate the unique aspects of biosimilars and their development programs.

Prior to his roles in medical affairs, he functioned as Regional Pharmacy Manager for Abbott, where he managed pharmacy operations for parenteral and nutritional products as well as key clinical relationships with major healthcare systems.

He received his Doctor of Pharmacy from the University of Southern California. Before joining industry, John practiced as a clinical pharmacist, specializing in parenteral nutrition and oncology.

Daniel Klein



Ira Klein, MD, MBA, FACP

Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Services

Ira Klein is Senior Director of Healthcare Quality Strategy in the Strategic Customer Group of Johnson & Johnson Health Care Services, advancing Janssen’s ability to deliver industry-leading value-based solutions to the new value-based marketplace. Key areas of focus in this role include building the business case for the Institute for Healthcare Improvement’s Triple Aim Solutions, delivering high value collaborations with ecosystem partners in the integrated delivery network, accountable care organizations, payer, and pharmacy benefit managers, and Janssen brand commercial strategy. This work is facilitated by a personal record of having worked on a variety of national quality and policy committees in Washington, DC, and with many medical specialty societies and patient advocacy groups. Previously, he was National Medical Director, Clinical Thought Leadership, Aetna, capping a 10-year career in the national payer space. During this time, he founded the Oncology Solutions team, creating and administering value-based and medical home contracts in oncology. In addition, during his time at Aetna he oversaw advanced analytics in population health and novel benefit designs for large self-insured employers, and developed wellness and chronic care programs that innovated in value-based care and behavioral motivational theory.

Prior to Aetna, he led the quality, cost, and care management area for the Bayshore Community Health System, including inpatient, outpatient, subacute, and long-term care services. This included oversight of all utilization management, JCAHO credentialing, CMS quality programs, and medical staff management. Prior to that, he was Chief Medical Officer of Elderplan, a CMS-enacted Medicare Demonstration Project in New York City serving the frail elderly. In this role, he reorganized a pharmacy benefit structure for Medicare-eligible members (5 years prior to CMS Part D), created coordinated care programs for multiple morbidities, and led quality and clinical reporting to governmental agencies. He began his career practicing internal medicine for 7 years at Robert Wood Johnson Medical School as Assistant Professor in the Division of General Internal Medicine.

He holds a Bachelor of Science degree from Rutgers, The State University of New Jersey, College of Pharmacy, a medical degree from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and a Masters in Business Administration from Rutgers University, graduating with honors from all 3 programs. He has a personal interest in health information technology and data security, previously certified in the medical health information technology area.

Michael Kolodziej, MD



Brian Korb



Crystal Kuntz

Vice President, Healthcare Policy & Research, Biotechnology Innovation Organization (BIO)

Crystal Kuntz is Vice President for Healthcare Policy and Research at the Biotechnology Innovation Organization (BIO), where she directs the association’s policy efforts related to Medicare, Medicaid, health reform, and economic trends and policies impacting BIO member companies.

Prior to BIO, Crystal was Vice President for Policy and Regulatory Affairs at America’s Health Insurance Plans, where she focused on policy and regulatory issues related to the implementation of the Affordable Care Act as well as prescription drug policy. Previously, she served as Senior Director for Policy at Coventry with a focus on Medicare as well as the implementation of healthcare reform. In addition, she served in senior policy roles at 2 pharmaceutical companies—Astellas Pharma US and Novartis. Before moving to the private sector, she led legislative and policy efforts related to the Medicare Advantage program and Part D within the Office of Legislation at the Centers for Medicare & Medicaid Services. There, she was part of the team that worked on the passage of the Medicare prescription drug benefits in 2003 and its early implementation.

She received her undergraduate degree in government and international affairs from Augustana College and has a Masters in public administration from Syracuse.

Rick Lee, MHA

Executive Chairman, CancerLife

Director, M3 Information

Rick Lee has made a career in the creation and sales of specialty healthcare applications and services sold to employers and health plans. He is currently Executive Chairman of CancerLife and Director of M3 Information. He was one of the early architects of the managed mental health (1982) and disease management (1994) industries. Since 2006, he has been toiling in the behavioral change vertical, first as President of Magellan’s Employee Assistance Program Division; then as Founder and Chief Executive Officer of Healthrageous, a behavioral change company launched in 2009 by Partners HealthCare, sold to Humana in September 2013. Most recently, Rick led an investor syndicate in the acquisition of MeYou Health from Healthways in June 2016. He served as the company’s Chief Executive Officer in Boston, MA, until 2017.

He founded Quality Oncology, a cancer disease management firm, in 1995 and was instrumental in the company’s growth and ultimate sale to Matria Healthcare in 2003. In the late 1980s, he was part of the founding team of Value Health, a specialty managed care company that grew to a $1.5-billion initial public offering in 3.5 years.

He is a graduate of Harvard College and the University of Washington School of Public Health, where he received a Masters in Healthcare Administration. Rick began his career in Washington, DC, where he worked for Congressman David Stockman and then rose to be #2 at the National Business Group on Health. He has often been characterized for thinking outside of the box, and coloring outside the lines. He currently sits on the board at CancerLife, M3 Information, and Archetype Solutions Group, and advises and mentors entrepreneurs.

Douglas Long

Vice President, Industry Relations, IQVIA

Douglas Long is Vice President, Industry Relations, IQVIA, the world’s largest pharmaceutical information company and has been with them since 1989. IQVIA offers services to the pharmaceutical industry in more than 101 countries around the world. His fundamental task is to help secure data for all existing and new databases supported by IQVIA; manage supplier, manufacturer, and association relationships; and develop information for data partners. As direct consequence of his involvement in these areas, he has considerable experience with, and a unique perspective on, the changing US and global healthcare marketplace and pharmaceutical distribution.

He is a frequent Industry speaker for the Health Distribution Management Association, National Association of Chain Drug Stores, Food Marketing Institute, National Council of Prescription Drug Programs, Pharmaceutical Care Management Association, National Community Pharmacists Association, International Federation of Pharmaceutical Wholesalers, Generic Pharmaceutical Association, Biotechnology Innovation Organization, Academy of Managed Care Pharmacy, Pharmaceutical Research and Manufacturers of America, Healthcare Supply Chain Association, and more. He was recently the opening speaker at the US Department of Health & Human Services’ Pharmaceutical Forum on Innovation, Access, Affordability, and Better Health. His topic was the balance between innovation and smarter spending.

Douglas is the recipient of the 2016 International Federation of Pharmaceutical Wholesalers’ Leadership Award. This award is given to an industry leader who has demonstrated a commitment to international collaboration and information sharing to assist the International Federation of Pharmaceutical Wholesalers on its mission to help members and stakeholders advance the safe, efficient, and continuous access to pharmaceuticals worldwide through the promotion of good distribution practices and services.

He also received the distinguished Harold W. Pratt Award in 2011, which recognizes individuals whose activities have contributed to the promotion, recognition, and improvement of the practice of pharmacy within the chain drug industry. Prior to receiving the Pratt Award, he was honored with the Healthcare Distribution Management Association’s Nexus Award for lifetime achievement in 2004, the IMS’ prestigious Summit Award in 2003, and the IMS CEO Team award in 2013.

Before joining IMS Health, he held positions at Nielsen Market Research for 16 years in various sales and marketing capacities. A native of Illinois, Doug received a Bachelor of Arts from DePauw University and holds a Masters in Business Administration in management from Fairleigh Dickinson University, Teaneck, NJ.

Ellen Lukens



Steve Lundquist



Sumner Madden



Ash Malik

President, Advanced Analytics Division, PrecisionQ Intregra Connect

Ash Malik is President, Advanced Analytics Division, PrecisionQ Integra Connect, where he is responsible for designing data- and analytics-driven solutions to enhance precision care products and services offered to patients, physicians, and payers by pharmaceutical and genomic-based life science companies. Prior to PrecisionQ Integra Connect, Ash was Partner, Healthcare Industry Advisory, at the Strategy& group in PricewaterhouseCoopers, where he served clients primarily in oncology and precision medicine on opportunities related to growth, product commercialization, and enterprise-wide strategy design. In addition, he served as Portfolio Director, Global Scientific Strategy, and Marketing Director, Commercial Operations, at Merck, where he participated in developing its US and global scientific strategy for metabolic diseases as well as international commercial operation requirements for biosimilars. Prior to Merck, he was with French multinational bioMeriéux, heading its divisional strategy to introduce molecular and genomics products in US and European markets.

Ash holds a Masters in biochemical engineering from Duke University and a Masters in business administration from the Kenan-Flagler Institute at University of North Carolina, Chapel Hill.

DeWayne Manning, RPh



Maurie Markman, MD



Rusty Massey



William McGivney, PhD



John McManus



Geoff Meacham, PhD



Tom Michaels

Senior Vice President, Sales, Vivaleas

Tom Michaels is an accomplished executive with strong sales, account management, market access, and new product launch experience. He is currently Senior Vice President, Sales, at Vivaleas, a patient-centered pharmaceutical services organization. He held numerous leadership roles in his 27 years at Novartis before moving to Diplomat Specialty Pharmacy in 2012 as Senior Vice President, Sales and Account Management.

In addition to sales leadership, Tom has in-depth experience in account management, integrated delivery networks, and specialty pharmacy that is vital in the complex world of healthcare today. He is a strong business leader with a proven track record of leading teams, setting strategic plans, and exceeding sales goals. He has led specialty product launches in the pharma and specialty pharmacy settings. Tom has built extensive relationships across payer, pharma, and provider groups. He has a focus on understanding customer needs and bringing value-based solutions to them. Tom has a passion for improving patient care and has helped provide added resources for education, copay funding, and adherence programs.

Tom graduated from Central Michigan University with a Bachelor’s degree in marketing, economics, and information systems analysis. He is also an alumnus of the University of Michigan’s Executive Education program.

Robert S. Miller, MD



Annastasiah Mudiwa Mhaka, PhD

Co-Founder, Alliance for Artificial Intelligence in Healthcare

Senior Advisor, Adjuvant Partners

Annastasiah Mudiwa Mhaka is an experienced life sciences executive, investment professional, and biotech entrepreneur with a passion for global health. Leveraging expertise in biomedical discovery, technology development, care delivery, and fundraising, she creates transformative healthcare advances impactful on a global scale. Utilizing her experience in multidisciplinary approaches, she co-founded the Alliance for Artificial Intelligence in Healthcare, a global organization dedicated to resolving the myriad challenges facing the growing field of artificial intelligence and machine learning-based healthcare solutions. She is also Senior Advisor for Adjuvant Partners, where she supports business development and transactions for advanced technologies to industry and academia with a focus on regenerative medicine, computational drug discovery, machine learning, and artificial intelligence.

In addition to her proven track record of more than 50 deals in the private and public sectors, she has generated more than $200 million in deliverables within the drug development and nanotechnology sectors.

She received her PhD in cellular and molecular medicine from Johns Hopkins Medicine, where she developed a clinical phase oncology drug, and attained her Bachelor of Science in chemistry (Highest Honors, Summa Cum Laude) from the University of Pittsburgh.

Marcus Neubauer, MD

Chief Medical Officer, The US Oncology Network

Marcus Neubauer is Chief Medical Officer for The US Oncology Network (a McKesson company). He has been with McKesson since March 2013. From June 2011 to March 2013, he practiced medical oncology as Associate Professor at the University of Kansas; prior to that he was Medical Oncologist at the Kansas City Cancer Center for 18 years. He has also practiced medicine part-time at the Seattle Cancer Care Alliance for 5 years.

He is a Founding Member and current Chair of The US Oncology Network Pathways Task Force, the committee responsible for developing and updating the industry-leading, evidence-based level 1 pathways. He leads the collaboration with the National Comprehensive Cancer Network (NCCN) to build a premium set of guidelines and pathways that will assist the oncology community in driving value-based, high-quality cancer care. The combined product is called Value Pathways powered by NCCN. His area of interest is the emergence of value-based care models and practice transformation to provide value-based care.

He received his Bachelors of Science degree at the University of Washington in 1984 and his medical degree at the University of Kansas in 1988. He completed his oncology/hematology fellowship at the University of Washington in 1993. He is on the editorial board for the Journal of Oncology Practice, and has served as Co-Chair of the Lung Cancer Committee for US Oncology Research for 6 years.

Dr Neubauer resides in his native hometown, Seattle, Washington with his wife, Michele. He has 2 children.

Brenda Nevidjon, RN, MSN, FAAN



Everett Neville, RPh



Ben Newton, PhD



Amy Niles, MBA



Kimberly Noonan, PhD



Andrew Norden, MD, MPH, MBA



Kavita Patel, MD, MS, FACP



Pamela M. Pelizzari, MPH

Principal and Senior Healthcare Consultant, Milliman

Pamela M. Pelizzari is a Principal and Senior Healthcare Consultant at Milliman in New York, NY. She specializes in the development and management of episode-based payment methodologies. She joined the firm in 2014. Prior to joining Milliman, Pamela served as a Senior Technical Advisor at the Centers for Medicare & Medicaid Services, where she was responsible for developing and implementing novel payment methodologies to transform healthcare delivery and payment nationwide. She played a key role in designing the National Bundled Payments for Care Improvement initiative, with thousands of participants nationally. She also led the development of an oncology episode-based payment model as well as other specialty physician–focused bundled payment models.

She has a broad background in integrated delivery system administration and healthcare payment reform. She has worked in the clinical and payer settings, and has experience in alternative risk contracting strategies. Previously, Pamela has worked at an academic medical center, building consensus for redesigning care delivery among diverse stakeholders, including physicians, administrators, and patient advocates.

She has particular expertise in the analysis of healthcare claims and the development of episode-based payment definitions and benchmarking methodologies. Pamela also has experience implementing prospective and retrospective payment methodologies, including developing gain-sharing methodologies, claims adjudication techniques, and quality monitoring programs.

In recent years, Pamela has published papers in academic journals, such as Lancet and Circulation. She has also spoken at numerous national conferences on the topic of episode-based payment models and methodologies.

Pamela received her Bachelor of Arts degree in community health and her Bachelor of Science degree in applied mathematics from Brown University, Providence, RI. She obtained her Master of Public Health degree in healthcare policy and administration from Johns Hopkins University Bloomberg School of Public Health.

Steve Peskin, MD, MBA, FACP



Chad Pettit



Scooter Plowman, MD, MBA, MHSA



Bruce Pyenson, FSA, MAAA

Principal and Consulting Actuary, Milliman

Bruce S. Pyenson is Principal and Consulting Actuary with Milliman in New York, NY. He joined the firm in 1987. Bruce’s practice uses data science and actuarial science to address pressing issues in healthcare. In his career, he has consulted to almost every sector of the healthcare industry, including accountable care organizations, employers, advocacy groups, insurers, and the biotechnology industry. Many of his projects involve integrating analytics from financial, clinical, and operational models.

In recent years, client projects have included the cost-benefit of lung cancer screening, the cost advantage of computed tomography colonography, the effect of changes in exchange benefit design, marginal cost analyses using risk adjustment methodologies, feasibility analyses for accountable care organizations, restructuring of disease management processes, and actuarial cost/benefit evaluations for pharmaceutical manufacturers.

In 2016, Bruce was appointed to a 3-year term as Commissioner of the Medicare Payment Advisory Commission, serving in a position reserved for an actuary. He was on the board of the Health Project (Koop Awards) from 2010 to 2016.

Bruce has co-authored approximately 30 peer-reviewed publications on topics ranging from lung cancer screening to survival in hospice, medication errors, and reinsurance for expensive biotechnology products. He was the editor and co-author of Managing Risk: A Leader’s Guide to Creating Successful Managed Care Provider Organization (AHA Publishing, 1998) and Calculated Risk: A Provider’s Guide to Assessing and Controlling the Financial Risk of Managed Care (American Hospital Publishing, 1995). He has also authored several Milliman research reports on topics such as obesity, hepatitis C, hospital outpatient trends, healthcare reform, and programs for the disabled elderly. He is a frequent speaker on issues related to system change.

He is a Fellow of the Society of Actuaries and a member of the American Academy of Actuaries.

Michael Reff, RPh, MBA

Founder and Executive Director, National Community Oncology Dispensing Association

Manager, The Patient Rx Center, Hematology/Oncology Associates of Central New York

Michael Reff is Founder and Executive Director of the National Community Oncology Dispensing Association, the first patient-focused organization dedicated to proactively help shape the oncology value proposition with regard to in-office dispensing. In addition, he continues practicing at Hematology/Oncology Associates of Central New York, where he established The Patient Rx Center, a medically integrated dispensing service focused on positive patient experiences with specialty medications.

He serves on the American Society of Clinical Oncology’s Quality Oncology Practice Initiative Steering Group Task Force. He also served on the Association of Community Cancer Centers’ Editorial Board, Government Affairs Committee, National Renal-Cell Carcinoma Advisory Committee, and Dispensing Pharmacy Project Committee. He shares his passion for patients with regard to the importance of the continuity of care for oral oncolytics through delivering presentations and publishing articles. He has extensive pharmaceutical industry experience spanning many disciplines, including oncology research, oncology sales, corporate compliance, international supply chain, and biologics manufacturing.

He received his Bachelor degree in pharmaceutical sciences and administration from Albany College of Pharmacy of Union University, and obtained his Master of Business Administration in finance from Le Moyne College.

Scott Reid, PharmD



Robert Rifkin, MD, FACP



Darin T. Rubin, MPH, MBA

Founding Partner and Managing Director, Dedham Group

Co-Founder and Partner, Pulse Digital

Darin T. Rubin has spent the past 20 years as a healthcare strategist focusing on the oncology and specialty therapeutics landscape and drawing upon a knowledge base of biomedical sciences, epidemiology, managed markets, distribution models, and commercialization strategy. As Founding Partner and Managing Director of the Dedham Group, a leading oncology and specialty strategy consultancy, his work centers on advising management of pharmaceutical and biotechnology clients across a multitude of specialty therapeutic areas, technology platforms, and regional access ecosystems.

At the forefront of local level access strategies that engage emerging access influences (eg, pathways, alternative payment models, quality and value dynamics, digital therapeutics, molecular diagnostics, technology-based partnerships), Darin has helped his clients anticipate, target, and execute to address rapidly evolving customer and competitive needs. He is also Partner and Co-Founder of Pulse Digital, a specialty therapeutics quality and value data provider.

He completed a Master in Public Health in healthcare policy and management from Columbia University, a Master of Business Administration in healthcare management from the University of Connecticut, postgraduate studies in molecular biology at Columbia University, and a Bachelor of Science in biochemistry from the University of Vermont.

Morrie Ruffin



Michael Ruiz de Somocurcio, MBA

Vice President, Payer and Provider Collaboration, Regional Cancer Care Associates

Michael Ruiz de Somocurcio is Vice President, Payer and Provider Collaboration, for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and the Centers for Medicare & Medicaid Services, and supporting growth strategies in new and existing markets. Prior to joining Regional Cancer Care Associates, he spent more than 15 years on the health plan side working for national, regional, and start-up health plans. Most recently, he held Chief Operating Officer and Vice President positions at Amerigroup, Oscar Insurance, and AmeriHealth NJ, where he led network contracting, strategic initiatives, and medical cost containment.

Throughout his career, he has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals, and physician groups, and he speaks nationally on these topics.

He received his Bachelor of Science degree in business administration from The College of New Jersey and a Master in Business Administration from Rutgers, The State University of New Jersey.

Peter Saltonstall



Marc Samuels, JD, MPH



Chuck Saunders



Dennis Scanlon, PhD



Theresa Schmidt, MA, PMP, CSPO



Jeffrey Scott, MD



Brian Seiz, PharmD



John Simmons, PhD



Greg Simon, JD



Surya Singh, MD



Stan Skrzypczak



Alfred Slanetz, PhD



Jayson Slotnik, JD, MPH

Principal and Co-Founder, Health Policy Strategies

Jayson S. Slotnik is Principal and Co-Founder of Health Policy Strategies, a Washington, DC–based consulting firm representing innovative biotechnology, pharmaceutical, device, and diagnostic companies. Prior to establishing Health Policy Strategies, he served as Vice President, Reimbursement and Innovation Strategies, United BioSource Corporation, where he was responsible for developing technology-related marketing and sales strategies for current internal and new external customers in the branded specialty pharmaceutical space. He partnered with the business development team to market technology strategies to more than 20 branded specialty manufacturers. In addition, he maintained his policy practice, which helped distinguish United BioSource Corporation’s market access technology as well as affording his clients the ability to have the business drive the policy and not the reverse.

Before joining United BioSource Corporation, Jayson practiced law at 2 prominent Washington, DC, law firms, where he counseled clients on many complex healthcare regulatory and legal issues related to coverage, coding, and reimbursement. Before returning to private practice, Jayson served as the initial Director, Medicare Reimbursement and Economic Policy, Biotechnology Industry Organization, the industry’s leading advocacy group. He served as the liaison between Biotechnology Industry Organization and the US Congress, Centers for Medicare & Medicaid Services, and other federal agencies to implement market access policies that stimulate and reward innovation while maintaining appropriate patient access to cutting-edge therapies.

He specializes in, and counsels clients on, the impact that Medicare and Medicaid coverage, payment, reimbursement, coding, and government policies have on commercial success. He also has experience as a healthcare strategist with demonstrated success in developing and implementing pre- and postlaunch strategies as well as life-cycle management tools for pharmaceutical, biotechnology, diagnostic, and device manufacturers.

He serves on the editorial boards for Value-Based Cancer Care and Specialty Pharmacy Times. He speaks regularly at various healthcare reform and market access conferences.

He received a Bachelor of Arts degree in English from the University of Rochester, his Master in Public Health with a concentration in epidemiology and biostatistics from George Washington University, and his Juris Doctor degree in health law from the University of Maryland School of Law.

Ipsita Smolinski, MBA, MPH



Mark Soberman, MD MBA FACS



David Spetzler, MS, MBA, PhD



Eric Sredzinski, PharmD



Josh Stein, MBA

Chief Executive Officer and Co-Founder, AdhereTech

Josh Stein is Chief Executive Officer and Co-Founder of AdhereTech, a company that makes patented smart medication bottles to track and improve adherence for patients on specialty medications. AdhereTech’s smart bottles are currently distributed from most of the largest specialty pharmacies in the United States, and they are used for many of the top specialty medications as well. On average, AdhereTech improves adherence by approximately 20% and time on therapy by more than 30%.

Josh has been a featured speaker at TEDMED, National Institutes of Health, Cleveland Clinic Medical Innovation Summit, South by Southwest, and many other health and technology conferences.

He earned a Master in Business Administration from the Wharton School, University of Pennsylvania, and a Bachelor of Arts in economics, finance, and legal studies from Washington University in St. Louis, MO.

Charles A. Stevens, JD, MBA

Vice President and Global Lead, Access, Commercialization, and Communications, ICON

Charles “Chuck” Stevens leads ICON’s global Access, Commercialization, and Communications business unit, which includes MediMedia Managed Markets, Complete Healthcare Solutions, Pricing and Market Access Consulting, Health Economics & Outcome Research, and Patient Insight teams. The group consists of more 375 commercialization professionals.

He has 25 years of biopharmaceutical industry experience, including responsibility for strategic reimbursement, pricing, public and private payer strategy, HUB programs, product distribution/channel management, government price reporting, ex-US Health Technology Assessment submissions, and pharmacoeconomic modeling for both commercialized and noncommercialized products. He has specialized expertise in hematology, oncology, infectious disease, addiction medicine, central nervous system, and rare disorder/ultra-orphan drugs.

He has worked extensively on issues involving the Affordable Care Act, the Medicare Modernization Act of 2003, the Single Drug Pricer system, and obtaining product-specific Healthcare Common Procedure Coding System codes. In 2006, he was the first person to be successful in obtaining an individual product Healthcare Common Procedure Coding System from the Centers for Medicare & Medicaid Services (CMS) by making applications in advance of US Food and Drug Administration (FDA) product approval, resulting in the specific code being available at the time of product launch. He was a member of a biopharmaceutical consortium that successfully advocated for the Centers for Medicare & Medicaid Services’ expansion of recognized drug compendia supporting reimbursement and patient access to therapy in oncology.

Prior to joining ICON, he spent 9 years serving as Vice President and General Manager of PAREXEL’s Reimbursement and Market Access Consulting Practice. Previous to PAREXEL, he held commercial positions of increasing responsibility at the senior director level at Cephalon Oncology, Cell Therapeutics, Genetics Institute (Wyeth Oncology), and Abbott Laboratories.

He is a former Captain in the US Army Reserve and veteran of Operation Desert Storm. He is admitted to the Massachusetts Bar and the Supreme Court of the United States of America Bar. Chuck is a frequent presenter at international conferences, including the FDA/CMS Summit, and has been quoted in publications such as Barron’s, The Financial Times, PharmaVoice, FDA Week, and the Pink Sheet. He is a former member of the Government Affairs Committee of the National Association of Specialty Pharmacy and past member of International Society for Pharmacoeconomics and Outcomes Research’s Institutional Council and Comparative Effectiveness Research Workgroup. He is also a contributing editor for the Drug Information Association Global Forum.

He holds a Bachelor of Science degree in business administration from Northeastern University, a Masters in Business Administration from Clark University, and a Juris Doctorate from Suffolk University Law School. He also attended the Massachusetts Senior Executive Program at Harvard University’s John F. Kennedy School of Government.

Tricia Strusowski, RN, MS

Manager, Oncology Solutions

Tricia Strusowski is Manager of Oncology Solutions, a cancer-exclusive consulting firm with more than 40 years of experience, working collaboratively with healthcare professionals nationwide to implement comprehensive cancer care programs that enhance patient experience, improve hospital performance, and affect communities. With more than 34 years of experience in the oncology field, she has worked in a variety of roles, including an oncology nurse, nurse manager, case manager, and most recently, a clinical director overseeing a multitude of departments, including chemotherapy infusion, rehabilitation program, navigation, survivorship, multidisciplinary disease site centers, thoracic surgery, palliative care, oncology medical home program, wellness programs, and bone marrow coordinators and accreditation program.

Her passion is in navigation and patient- and family-centered care in the oncology landscape, and in conjunction with serving on multiple advisory boards, she implemented 15 multidisciplinary cancer centers, including breast, lung, head and neck, pancreatic, and various other tumor site–specific teams. She puts this rich work history to practice in consulting on the strategic development and implementation of oncology clinical programs within private practices, hospitals, and health systems across the country.

She has presented and published nationally and has participated in the development of oncology nurse navigator core competencies and the Academy of Oncology Nurse & Patient Navigators’ navigation metrics. She is Co-Chair of the American Cancer Society’s National Navigation Roundtable Evidence- Based Promising Practices.

She holds a Masters in healthcare administration and management from Wilmington University.

Ray Tancredi, RPh, MBA, CSP

Divisional Vice President, Specialty Pharmacy Development and Brand Prescription/Vaccine Purchasing, Walgreens

Ray Tancredi is Divisional Vice President, Specialty Pharmacy Development Brand Prescription/Vaccine Purchasing, at Walgreens, based in Deerfield, IL. He oversees a team responsible for all specialty pharmacy trade functions, such as specialty pharmacy product access, including limited distribution and relationships, managing manufacturer HUB services and referrals, contract negotiation, implementation and compliance, pharmaceutical programs and services, data analysis and reporting, request for proposal support, and coordinating clinical, patient services, new drug in-services, and education. In addition, he oversees management of strategic manufacturer accounts in an effort of maximize contracts and provide exceptional customer service.

Ray also oversees the team responsible for brand prescription drug launches and vaccine procurement, including flu vaccine, group purchasing organization relationships, and specialty pharmacy distributors.

He is President of the Specialty Pharmacy Certification Board and is a Certified Specialty Pharmacist (CSP Certificate 032).

He earned his Bachelor of Science in pharmacy from Temple University School of Pharmacy, and is a registered pharmacist in Pennsylvania and Florida. He also holds a Master of Business Administration in management from Eastern University.

Sean Tunis, MD, MSc



Norris Turner, PharmD, PhD

Vice President, Strategic Alliances and Measure Implementation, Pharmacy Quality Alliance

Norris Turner serves in the role of Vice President, Strategic Alliances and Measure Implementation, at Pharmacy Quality Alliance (PQA). In this role, he leads PQA’s efforts to develop and maintain relationships at the regional, state, and federal levels with government agencies, commercial payers, providers, and pharmacies to further PQA’s measure development and implementation efforts. PQA, as a measure developer, seeks to partner with entities to improve patient care and to do so in a measurable way through appropriate inclusion of performance measures into value-based care measure sets.

Prior to joining PQA, he worked in the pharmaceutical industry for 19 years and served with Janssen over the last 12 years. His most recent position was Director, Health Care Quality, Neuroscience, within the Strategic Customer Group, Johnson & Johnson Health Care Systems, where he focused on the overarching quality and value-based care reimbursement direction in the United States.

Over a 15-year period, he held a variety of positions with increasing responsibility at Pfizer, Purdue Pharma, and Janssen in phase 2 to 4 clinical development and investigator-initiated research in the therapeutic areas of psychiatry and pain.

He obtained his PharmD degree from the University of Michigan College of Pharmacy. He obtained his PhD in pharmaceutical chemistry at the University of California San Francisco, and he obtained his 2-Year Graduate Certificate in Health Policy from Thomas Jefferson University School of Population Health. He was recognized by the Pharmaceutical Research and Manufacturers of America as a 2016 We Work for Health Champion. He currently serves as a Board Member for the National Transitions of Care Coalition.

Dr Norris lives in Yardley, PA, with his wife, Denise, and 3 high school and college-aged children, and is an avid runner.

Clorinda Walley



Susan Weidner, MS

Senior Vice President, Analytics, IntrinsiQ Specialty Solutions

Susan Weidner is Senior Vice President, Analytics, at IntrinsiQ Specialty Solutions, where she is responsible for overseeing data analytics/business intelligence, and the software development and implementation initiatives for oncology, urology, and multispecialty customers.

She has gained more than 20 years of healthcare and pharmaceutical experience through executive leadership positions at SafeNet Consulting, Inform Genomics, and MGI Pharma (now Eisai). She has led the design, development, and implementation of innovative healthcare solutions, including those driven by healthcare informatics. Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers, and providers in demonstrating the value of their products and/or their organizations.

A graduate of Eastern Kentucky University, where she earned a Bachelor of Science in mathematics and statistics, she also holds a Masters in biostatistics from the Ohio State University.

William (Bill) Winkenwerder Jr, MD



Jedd Wolchok, MD, PhD



William Yoon, PharmD, MBA



Danielle Ziernicki, BS, RPh, PharmD

Head, Medical and Regulatory Affairs, The Dedham Group

Danielle Ziernicki, Head of Medical and Regulatory for The Dedham Group, a pharmaceutical strategy consulting firm, has more than 18 years of pharmaceutical business experience. Prior to her current position, she spent more than 17 years working at Johnson & Johnson in various superior roles. After completing a postdoctoral residency in drug information at Janssen, she began in the Janssen Medical Information Department, serving as a strategic partner to sales and marketing organizations by providing scientifically accurate medical information for marketed products. Next, she transitioned to Janssen Global Regulatory Affairs and worked for almost 10 years as Director in the Global Regulatory Policy and Intelligence Department. After completing the Jefferson Health Policy certificate program, she served as Health Quality Lead for Immunology and Oncology at Johnson & Johnson, ensuring company strategies aligned with the United States overarching quality and reimbursement direction.

In addition to pharmaceutical industry experience, she is currently Adjunct Regulatory and Clinical Marketing Professor at the University of the Sciences in Philadelphia. Her experience also includes retail and hospital pharmacy; she worked for 10 years as an on-call hospital pharmacist.

She is a licensed Pennsylvania pharmacist and received her Bachelor in Science and PharmD degrees at Philadelphia College of Pharmacy, University of Sciences. She completed her a postdoctoral residency in drug information at Janssen and holds a graduate certificate in health policy from Thomas Jefferson University School of Public Health.

Burt Zweigenhaft